Skip to content
The Policy VaultThe Policy Vault

Procysbi (cysteamine bitartrate)Blue Cross Blue Shield of Alabama

Any indication supported in compendia for the requested agent and route of administration

Preferred products

  • Cystagon (immediate-release cysteamine)

Initial criteria

  • ONE of the following:
  • - The patient has a diagnosis of nephropathic cystinosis OR
  • - The patient has another FDA labeled indication for the requested agent and route of administration OR
  • - The patient has an indication that is supported in compendia for the requested agent and route of administration
  • AND if the patient has an FDA labeled indication, then ONE of the following:
  • - The patient’s age is within FDA labeling for the requested indication OR
  • - There is support for using the requested agent for the patient’s age for the requested indication
  • AND ONE of the following:
  • - The patient has tried and had an inadequate response to Cystagon (immediate-release cysteamine) OR
  • - The patient has an intolerance or hypersensitivity to Cystagon that is not expected to occur with the requested agent OR
  • - The patient has an FDA labeled contraindication to Cystagon that is not expected to occur with the requested agent
  • AND The prescriber is a specialist in the area of the patient’s diagnosis (e.g., nephrologist) or has consulted with such a specialist
  • AND The patient does NOT have any FDA-labeled contraindications to the requested agent

Approval duration

12 months